46 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease.
Amgen
Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes.
Pfizer
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.
Pfizer
Treatment of Obesity and Related Disorders with Acetyl-CoA Carboxylase Inhibitors.
Therachem Research Medilab (India)
Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors.
Takeda Pharmaceutical
Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors.
Takeda Pharmaceutical
Discovery of novel (4-piperidinyl)-piperazines as potent and orally active acetyl-CoA carboxylase 1/2 non-selective inhibitors: F-Boc and triF-Boc groups are acid-stable bioisosteres for the Boc group.
Taisho Pharmaceutical
Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors.
Abbott Laboratories
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.
Pfizer
Design, synthesis, and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors.
Takeda Pharmaceutical
Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.
Astrazeneca Research and Development
Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation.
Sanofi-Aventis Deutschland
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2.
Pfizer
(4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.
Taisho Pharmaceutical
Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase.
Bristol-Myers Squibb Research and Development
Synthesis of spiro[chroman-2,4'-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors.
Torrent Pharmaceuticals
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
Bristol-Myers Squibb Pharmaceutical Research Institute
N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-coA carboxylase inhibitors--improvement of cardiovascular and neurological liabilities via structural modifications.
Abbott Laboratories
Structurally Diverse Triterpene-26-oic Acids as Potential Dual ACL and ACC1 Inhibitors from the Vulnerable Conifer
Fudan University
Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents.
Abbott Laboratories
The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: polar region modifications.
Abbott Laboratories
Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
Abbott Laboratories
Novel Thienopyrimidines as Acetyl-CoA Carboxylase Inhibitors for Treating Liver Diseases.
Smith, Gambrell & Russell
Cyclohexanedione herbicides are inhibitors of rat heart acetyl-CoA carboxylase.
Eli Lilly
Synthesis and in vitro evaluation of novel spiroketopyrazoles as acetyl-CoA carboxylase inhibitors and potential antitumor agents.
Xuzhou Medical University
Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors.
Takeda Pharmaceutical
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Pfizer
The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor.
Takeda Pharmaceutical
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Takeda Pharmaceutical
Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors.
China Pharmaceutical University
Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.
Shionogi
Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.
Takeda Pharmaceutical
Benzimidazole compounds and derivatives as EGFR inhibitors
Boehringer Ingelheim International
Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist
Suven Life Sciences